If a subject cannot have a CT scan [e.g. allergy to contrast dye], an MRI should be performed. CT scan may be done within ±7 days of EOC. • Clinical assessment of tumor status using modified RECIST for assessment of response in MPM4 and irRC47 • Pulmonary function tests: VC, FVC and FEV 1 for Cohort 2 only • Physical examination • ECOG performance status • Resting 12- lead electrocardiogram • Vital signs (BP, pulse, respiratory rate, temperature, pulse oximetry ) and weight • Blood draws for clinical hematology, serum chemistry • Blood draw (serum and plasma) for tumor marker(s) (See Section 5.3) • AEs and concomitant medications review • Blood draw for isolation of PBMC (up to 200 mL) ( See Section 5.3) • Blood draw for Lm- and mesothelin- specific immunity assays ( 10 m L) (See Section 5.3) • Optional core needle biopsy; may be done any time after final dose in course (see Section 5.3) Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 45 5.2.3 Study Follow- up Period /End of Study (EOS) Subjects will return to the clinic for follow -up approximately 4 weeks after their EOC visit and every 8 weeks thereafter until disease progression or investigator determines subject is no longer receiving benefit from treatment (if subject continues treatment beyond progression). Subjects who are clinically stable and continue to meet dosing eligibility will receive maintenance vaccinations (with or without Cy) at every follow -up visit . Subjects may continue on treatment with radiographic disease progression if subject is clinically stable and investigator believes the treatment is providing benefit. All subjects will complete an EOS visit no more than four weeks following the final dose of study medication or prior to receipt of other cancer -related treatment. If the EOS visit occurs earlier than 4 weeks, a safety follow-up telephone call on Day 28 (+/- 7 days) is required; document contact in the study records. The following evaluations will be done at each follow -up (FU) visit and at the end of study ( EOS ) visit: • Symp tom- directed physical examination • ECOG performance status • Vital signs (BP, pulse, respiratory rate, temperature, pulse oximetry ) and weight (day 1 only) • Blood draws for clinical hematology, serum chemistry • AEs and concomitant medications review • For eligibl e subjects receiving maintenance vaccinations (MVs), CRS -207 (without Cy [Cohort 1] or with Cy [Cohort 2] ) will be administered at every follow- up visit . CRS -207 and Cy will be administered following the same procedures stated in Section 5.2.2.1. Subjects will be monitored for at least 2 hours after each infusion or until they are considered clinically stable . Blood draw s for clinical labs may be done up to 3 days prior to CRS -207 dosing ( Cohort 1) or 2 days prior to Cy for subjects receiving Cy (Cohort 2). Subjects will be contacted by phone to assess AEs and concomitant medications 1 day after CRS -207 infusion. Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 46 • Blood will be collected to assess clearance of CRS -207 at EOS Visit. For subjects with a central line port, a blood sample will also be taken through the port. This blood collection must be taken prior to administration of the EOS antibiotics. • To eliminate any potentially residual CRS -207, subjects will initiate a 7 -day course of antibiotics at the EOS visit and prior to receiving any subsequent cancer -related therapy (refer to Section 5.2.2.5). In accordance with good medical practice, any ongoing AE present at end of the study , including a clinically significant laborat ory test abnormality, which is determined by the investigator as possibly or probably related to the study investigational agents, will be followed until resolved, until the event stabilizes and the overall clinical outcome has been ascertained, or until the subject is lost to follow-up. 5.3 LABORATORY EVALUATIONS 5.3.1 Immune Monitoring Assessments Peripheral blood mononuclear cells and serum Peripheral blood mononuclear cells ( PBMC s) and serum will be collected at various time points as listed in Table 2, prior, during and post treatment to assess Lm- and mesothelin- specific immunity. T cell responses to mesothelin will be considered positive when the frequency of specific responses are ≥ 1 in 105 CD8+ peripheral blood lymphocytes (PB L) above the control sample and increased by at least 2 -fold compared to baseline. T cell responses to Lm (LLO ) will be considered positive when specific T cell frequencies were ≥ 1 in 105 PBMCs and increased by at least 2 -fold compared to baseline. Collection Briefly, up to 200 mL of whole blood will be collected in green top tubes (heparin sulfate) or heparinized syringes . At NCI site, p lease page 102 -11964 (Gareth Peters or alternate tech nician from Dr.